Results 201 to 210 of about 45,788 (261)

Escalating Doses of Buprenorphine for the Treatment of Buprenorphine-Induced Opioid Withdrawal. [PDF]

Cureus
Laxton SJ.
europepmc   +1 more source

Mindfulness‐Based Intervention Improves Cognitive Function in Patients With Schizophrenia in Remitted: A Randomized Controlled Trial

International Journal of Methods in Psychiatric Research, Volume 35, Issue 4, December 2026.
ABSTRACT Background Patients with schizophrenia exhibit deficits in facial emotion recognition (FER), attention, P300, and quality of life (QoL), which severely hinder functional recovery. This study aims to explore the effects of mindfulness‐based intervention (MBI) on these outcomes and the potential mediating mechanisms.
Peipei Lyu, Xiuxia Yuan, Yan Zhang, Qiong Wu, Yibing Zheng, Yichen Su, Xueqin Song   +6 more
wiley   +1 more source

Adapting a Risk Prediction Tool for Neonatal Opioid Withdrawal Syndrome. [PDF]

Pediatrics
Reese TJ, Wiese AD, Leech AA, Domenico HJ, McNeer EA, Davis SE, Matheny ME, Wright A, Patrick SW.   +8 more
europepmc   +1 more source

Opioid Dependence and Withdrawal

Daizy Tak, Meharunisha Siddiqui, Akshita Khinchi, Hardik Prajapat, Insiya Ogna, Bhargavi Singh Chauhan   +5 more
openaire   +2 more sources

Characterization of the Lysophosphatidic Acid Receptor 5 Antagonist RLPA‐76 as a Novel Analgesic in Male Rats and Mice

Pharmacology Research &Perspectives, Volume 14, Issue 6, December 2026.
ABSTRACT Clinically used analgesics such as gabapentinoids and opioids have limited efficacy and adverse effects like abuse liability, and there is a dire need for novel analgesics with improved safety profiles. Since lysophosphatidic acid can induce neuropathic pain in rodents, LPA receptor antagonists have been investigated as potential analgesics ...
Kristen L. Woodhouse, Maowei Wang, Sai Ganesh Balaji Venkata Anupindi, Olatunbosun Adeoke, Dehui Zhang, Yanan Zhang, Jun‐Xu Li   +6 more
wiley   +1 more source

Treating Opioid Use Disorder and Opioid Withdrawal in the Context of Fentanyl. [PDF]

Annu Rev Clin Psychol
Martinez S, Ellis JD, Bergeria CL, Huhn AS, Dunn KE.   +4 more
europepmc   +1 more source

A small molecule PKCε inhibitor reduces hyperalgesia induced by paclitaxel or opioid withdrawal. [PDF]

JCI Insight
Gregory-Flores A, Bonet IJ, Desaivre S, Levine JD, McHardy SF, de Kraker HC, Clanton NA, LoCoco PM, Russell NM, Fleischer C, Messing RO, Marinelli M.   +11 more
europepmc   +1 more source

Efficacy of stochastic vibro-tactile stimulation for newborns at risk of neonatal opioid withdrawal syndrome. [PDF]

Pediatr Res
Singh R, Trinquart L, Koethe B, Cordova M, Rhein L, Bibi S, Fey J, Anderson A, Davis JM.   +8 more
europepmc   +1 more source

Optimal Drug, Optimal Dose, or Both in the Pharmacological Treatment of Neonatal Opioid Withdrawal Syndrome? [PDF]

Clin Pharmacol Ther
Kraft WK.
europepmc   +1 more source